Literature DB >> 7126259

Enzymes of salvage and de novo pathways of synthesis of pyrimidine nucleotides in human colorectal adenocarcinomas.

N K Ahmed, R C Haggitt, A D Welch.   

Abstract

The activity of uridine-cytidine kinase (Urd-Cyd kinase). a key enzyme in the salvage of pyrimidine nucleosides, averaged 0.86 +/- 0.16 (S.E.M.) nmole uridine phosphates . min-1 . (mg protein)-1 in fifty-three specimens of human colorectal adenocarcinomas. The activity of fluorouracil phosphoribosyltransferase (FUPRTase) in thirty-five carcinoma specimens averaged only 0.19 +/- 0.07 nmole fluorouridine phosphates . min-1 . (mg protein)-1. The activity of the last enzyme in the de novo pathway of biosynthesis of UMP, i.e. orotidine 5'-monophosphate (OMP) decarboxylase, averaged 0.21 +/- 0.04 nmole CO2 . min-1 . (mg protein)-1. The activity of Urd-Cyd kinase was increased approximately 2.3-fold, and that of OMP decarboxylase by about 91%, while that of FUPRTase was increased by only 27%, as compared to that of normal human colonic mucosa. Of the colorectal carcinomas studied, 72% were moderately differentiated, 21% poorly differentiated, and 7% well differentiated. The mean diameter of the fifty-three carcinomas was 5.5 cm, and pathologic staging led to classification of 15% as Dukes' A, 36% as Dukes' B, 47% as Dukes' C, and 2% as carcinoma in situ. No correlations between the level of the enzyme activities studied and any pathologic characteristics of the carcinomas could be discerned.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7126259     DOI: 10.1016/0006-2952(82)90058-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  Comparative levels of tissue enzymes concerned in the early metabolism of 5-fluorouracil in normal and malignant human colorectal tissue.

Authors:  P J Finan; P A Koklitis; E M Chisholm; G R Giles
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640

2.  Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.

Authors:  Y Shimamoto; A Fujioka; H Kazuno; Y Murakami; H Ohshimo; T Kato; A Matsuda; T Sasaki; M Fukushima
Journal:  Jpn J Cancer Res       Date:  2001-03

3.  Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2.

Authors:  Yuji Shimamoto; Katsuhisa Koizumi; Hiroyuki Okabe; Hiromi Kazuno; Yuko Murakami; Fumio Nakagawa; Akira Matsuda; Takuma Sasaki; Masakazu Fukushima
Journal:  Jpn J Cancer Res       Date:  2002-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.